EchoGo Amyloidosis vs Viz RV/LV
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A is designed for the early detection of cardiac amyloidosis through AI analysis of echocardiogram video clips, providing a diagnostic output for this specific heart condition. In contrast, Tool B automates right and left ventricular diameter measurements from CTPA scans to facilitate rapid pulmonary embolism risk stratification. While both are FDA-cleared, cloud-based AI tools that assist in cardiac-related diagnostics, they target different diseases, utilize distinct imaging modalities, and offer specialized insights for their respective clinical applications.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Ultromics' EchoGou00ae Amyloidosis is an AI-powered screening tool designed to aid in the early detection of cardiac amyloidosis from echocardiogram video clips. In contrast, Viz RV/LV by Viz.ai is an FDA-cleared AI algorithm that automates right and left ventricular diameter measurements from CTPA scans for rapid pulmonary embolism risk stratification.
EchoGou00ae Amyloidosis analyzes echocardiogram video clips, specifically 2D echocardiograms of an apical four-chamber view. Viz RV/LV processes volumetric CTPA (Computed Tomography Pulmonary Angiography) acquisitions to perform its analysis.
EchoGou00ae Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on its AI-powered analysis of echocardiographic markers such as ventricular volume, cardiac function, and myocardial movement. Viz RV/LV automates the measurement of right and left ventricular diameters to provide a crucial RV/LV ratio, and also offers annotated images showing these ventricular measurements.
EchoGou00ae Amyloidosis is designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7. Viz RV/LV functions as a seamless component of the Viz PE Solution, offering AI-powered alerts and notifications to care teams, and includes a HIPAA-compliant communication platform for care coordination.
For EchoGou00ae Amyloidosis, there is an NTAP Code ICD-10 XXE2X19 for inpatient analysis (Medicare-covered) and HCPCS Code C9786, Clinical APC Code 574 for outpatient analysis (covered by Medicare and select commercial insurers). Pricing details for Viz RV/LV are not publicly available, and specific reimbursement codes are not provided in the given information.
EchoGou00ae Amyloidosis is primarily designed to support Cardiology specialists. Viz RV/LV primarily supports specialists in Emergency Medicine, Pulmonology, and Radiology.